Compartilhar
Informação da revista
Vol. 46. Núm. S4.
HEMO 2024
Páginas S496 (outubro 2024)
Vol. 46. Núm. S4.
HEMO 2024
Páginas S496 (outubro 2024)
Acesso de texto completo
EFFICACY OF OLVEREMBATINIB IN THE TREATMENT OF REFRACTORY CHRONIC MYELOID LEUKEMIA: A SYSTEMATIC REVIEW AND SINGLE-ARM META-ANALYSIS
Visitas
286
CLL Furtadoa, GFM Filhob, MLMR Costac, LAMPL Lugoa, RM Delgadob, GCTB Netoc, PHF Grisid, GC Lirac
a Universidade Federal da Paraíba (UFPB), João Pessoa, Brazil
b Universidade Federal de Campina Grande (UFCG), Campina Grande, Brazil
c Faculdade de Medicina Nova Esperança (FAMENE), João Pessoa, Brazil
d Centro Universitário UNIFACISA, Campina Grande, Brazil
Este item recebeu
Informação do artigo
Suplemento especial
Este artigo faz parte de:
Vol. 46. Núm S4

HEMO 2024

Mais dados
Objective

To perform a systematic review and meta-analysis to evaluate the efficacy of Olverembatinib, a novel BCR::ABL1 tyrosine kinase inhibitor (TKI), in refractory chronic myeloid leukemia (CML).

Material and methods

PubMed, Embase and Cochrane database were searched, until June 2024, for randomized clinical trials (RCTs) that assess the efficacy of Olverembatinib in patients with CML, with or without T315I mutation, who have failed at least two prior TKI therapy. The primary outcomes were Major Molecular Response (MMR), Complete Cytogenetic Response (CCyR) and Major Cytogenetic Response (MCyR). Statistical analysis was performed using R-4.4.1. Heterogeneity was examined with I2 statistics.

Results

238 patients were included from 3 RCTs, with follow-up ranging from 0 to 5 years. The pooled analysis revealed an MMR of 0,4205 (95% CI [0,2789 - 0,5765]; p < 0,01); a CCyR of 0,5501 (95% CI [0,3529 - 0,7328]; p < 0,01) and an MCyR of 0,6548 (95% CI [0,4886 - 0,7902]. Heterogeneity was high across all outcomes, with I2 values of 85% for MMR, 88% for CCyR and 85% for MCyR.

Discussion

The results demonstrate that Olverembatinib has significant efficacy in achieving high rates of MMR, CCyR and MCyR in refractory CML patients. However, the high heterogeneity observed in all three outcomes suggests notable variability across studies. This variability likely stems from differences in baseline characteristics, including the number of prior TKI treatment lines and median treatment duration among study populations. The small number of studies included also contributes to this variability.

Conclusion

Olverembatinib shows promise as an effective treatment option for refractory CML. However, further research is warranted to elucidate the significant heterogeneity observed across studies, optimize treatment strategies, and provide more robust evidence of its efficacy.

O texto completo está disponível em PDF
Baixar PDF
Idiomas
Hematology, Transfusion and Cell Therapy
Opções de artigo
Ferramentas